Regeneron Pharmaceuticals (REGN) : Traders are bullish on Regeneron Pharmaceuticals (REGN) as it has outperformed the S&P 500 by a wide margin of 14.73% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 8.7%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 8.63% in the last 1 week, and is up 18.58% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 12.16% and the 50-Day Moving Average is 12.74%. Regeneron Pharmaceuticals, Inc. is up 12.85% in the last 3-month period. Year-to-Date the stock performance stands at -21.69%.
Regeneron Pharmaceuticals (NASDAQ:REGN): stock turned positive on Friday. Though the stock opened at $411.33, the bulls momentum made the stock top out at $425.88 level for the day. The stock recorded a low of $409.99 and closed the trading day at $425.12, in the green by 3.43%. The total traded volume for the day was 1,370,477. The stock had closed at $411.04 in the previous days trading.
Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.